The New York Stem Cell Foundation Research Institute (NYSCF) and Janssen Research & Development, a Johnson & Johnson company, have partnered to accelerate the development of precision medicines for neurodegenerative diseases.
NYSCF’s AI-powered platform, using automated stem cell systems, will be leveraged to identify new drug targets and therapies.
This collaboration combines NYSCF’s expertise in stem cell technology and automation with Johnson & Johnson’s drug development capabilities.
The goal is to create more effective treatments for patients suffering from these debilitating diseases by using patient-derived stem cells for large-scale drug screening.
The initiative represents a significant step towards advancing precision medicine in neurodegenerative disease research.
Listen to full podcast episode for more details:
